IS
ISI.F Ionis Pharmaceuticals Inc
- Market cap
- EUR 4.21B
- P/E
- -
- P/B
- 11.92x
- ROE
- -107.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ISI.F undervalued?
Graham numberThe Graham number of Ionis Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ionis Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Ionis Pharmaceuticals Inc yet.
Ionis Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pe…
Full company profileIonis Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ionis Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 347M | 508M | 600M | 1.12B | 729M | 810M | 587M | 788M | 705M | 944M | 1.01B |
| Gross Profit | 2.30M | 133M | 598M | 1.12B | 717M | 799M | 573M | 779M | 694M | 928M | 997M |
| Operating Income | -46.3M | 24.5M | -61.4M | 366M | -172M | -30.0M | -411M | -354M | -475M | -382M | -467M |
| EBITDA | - | 29.8M | -18.8M | 412M | -108M | - | -228M | -230M | -354M | -273M | -327M |
| Net Income | -86.6M | -5.97M | 274M | 294M | -451M | -29.0M | -270M | -366M | -454M | -381M | -423M |
| EPS | - | -0.05 | 1.98 | 2.10 | -3.21 | -0.21 | -1.90 | -2.54 | -2.87 | -2.34 | -2.54 |
| Balance Sheet | |||||||||||
| Total Assets | 912M | 1.32B | 2.67B | 3.23B | 2.39B | 2.61B | 2.53B | 2.99B | 3.00B | 3.52B | 2.91B |
| Total Liabilities | 813M | 903M | 1.48B | 1.55B | 1.55B | 1.84B | 1.96B | 2.60B | 2.42B | 3.03B | 2.52B |
| Shareholders' Equity | 99.6M | 331M | 1.05B | 1.47B | 843M | 772M | 573M | 387M | 588M | 489M | 394M |
| Cash & Short-term Investments | 84.7M | 130M | 279M | 683M | 1.89B | 2.12B | 1.99B | 399M | 242M | 372M | 296M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -112M | 174M | 603M | 346M | 35.9M | 30.8M | -274M | -541M | -501M | -269M | -542M |
| Capital Expenditure | 11.5M | 34.8M | 13.6M | 30.9M | 35.1M | 12.0M | 15.7M | 33.0M | 50.3M | 57.1M | 74.3M |
| Free Cash Flow | - | 136M | 585M | 309M | -5.16M | 12.9M | -294M | -574M | -551M | -326M | -617M |
| Ratios | |||||||||||
| ROE | -86.9% | -1.8% | 26.1% | 20.0% | -53.5% | -3.8% | -47.1% | -94.7% | -77.1% | -78.0% | -107.4% |
| ROA | -9.5% | -0.5% | 10.3% | 9.1% | -18.9% | -1.1% | -10.7% | -12.3% | -15.1% | -10.8% | -14.5% |
| Net Profit Margin | -25.0% | -1.2% | 45.6% | 26.2% | -61.9% | -3.6% | -46.0% | -46.5% | -64.4% | -40.4% | -41.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ionis Pharmaceuticals Inc dividends
Ionis Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Ionis Pharmaceuticals Inc
- Insiders 0.59%
- Institutions 99.41%
- Public & others 0.00%
- Shares outstanding 167M
- Free float 165M
Ionis Pharmaceuticals Inc company profile
- Company name
- Ionis Pharmaceuticals Inc
- Ticker
- ISI.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,485
- Fiscal year end
- December
- Address
- 2855 Gazelle Court, Carlsbad, CA, United States, 92010
- Phone
- 760 931 9200
- Website
- ionis.com
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Ionis Pharmaceuticals Inc management
10- Dr. Brett P. Monia Ph.D.Founder, CEO & Director · born 1961
- Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.Executive VP of Finance & CFO · born 1962
- Mr. Patrick R. O'Neil Esq.Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary · born 1974
- Dr. Eric E. Swayze Ph.D.Executive Vice President & Head of Research · born 1966
- Mr. Brian BirchlerExecutive Vice President of Corporate & Development Operations · born 1966
- Dr. Richard S. Geary Ph.D.Strategic Consultant · born 1958
- Dr. Eugene Schneider M.D.Executive VP, Chief Clinical Development & Operations Officer · born 1973
- Mr. Darren GonzalesChief Accounting Officer & Senior VP
- Dr. C. Frank Bennett BSc, Ph.D.Executive VP & Chief Scientific Officer · born 1957
- Mr. D. Wade Walke Ph.D.Senior Vice President of Investor Relations